Reckitt Kept Addiction Drugs Off Market: Antitrust Suit

By Daniel Wilson (February 14, 2013, 3:28 PM EST) -- Drug wholesaler Rochester Drug Co-Operative Inc. hit Reckitt Benckiser Inc. with a proposed class action in Delaware federal court Wednesday, accusing it of an anti-competitive scheme to keep generic rivals to opiate addiction treatment Suboxone off the market.

According to Rochester's complaint, Reckitt had illegally manipulated the U.S. Food and Drug Administration's regulatory systems, effectively extending its monopoly over the drug beyond a seven-year exclusivity period granted by the agency, causing purchasers to overpay for the drug.

"Reckitt cannot justify its scheme by pointing to any offsetting consumer benefit," Rochester said. "The enormous cost savings offered by generic drugs … outweigh...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!